Literature DB >> 9053451

Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.

D L Bodian1, S J Davis, B P Morgan, N K Rushmere.   

Abstract

The Ly-6 superfamily of cell surface molecules includes CD59, a potent regulator of the complement system that protects host cells from the cytolytic action of the membrane attack complex (MAC). Although its mechanism of action is not well understood, CD59 is thought to prevent assembly of the MAC by binding to the C8 and/or C9 proteins of the nascent complex. Here a systematic, structure-based mutational approach has been used to determine the region(s) of CD59 required for its protective activity. Analysis of 16 CD59 mutants with single, highly nonconservative substitutions suggests that CD59 has a single active site that includes Trp-40, Arg-53, and Glu-56 of the glycosylated, membrane-distal face of the disk-like extra-cellular domain and, possibly, Asp-24 positioned at the edge of the domain. The putative active site includes residues conserved across species, consistent with the lack of strict homologous restriction previously observed in studies of CD59 function. Competition and mutational analyses of the epitopes of eight CD59-blocking and non-blocking monoclonal antibodies confirmed the location of the active site. Additional experiments showed that the expression and function of CD59 are both glycosylation independent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9053451      PMCID: PMC2196035          DOI: 10.1084/jem.185.3.507

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  45 in total

1.  Determination of the active site of CD59 with synthetic peptides.

Authors:  Y Nakano; T Tozaki; N Kikuta; T Tobe; E Oda; N Miura; T Sakamoto; M Tomita
Journal:  Mol Immunol       Date:  1995-03       Impact factor: 4.407

2.  Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins.

Authors:  B Kieffer; P C Driscoll; I D Campbell; A C Willis; P A van der Merwe; S J Davis
Journal:  Biochemistry       Date:  1994-04-19       Impact factor: 3.162

3.  Topology of the CD2-CD48 cell-adhesion molecule complex: implications for antigen recognition by T cells.

Authors:  P A van der Merwe; P N McNamee; E A Davies; A N Barclay; S J Davis
Journal:  Curr Biol       Date:  1995-01-01       Impact factor: 10.834

Review 4.  Complement inhibitory therapeutics and xenotransplantation.

Authors:  U S Ryan
Journal:  Nat Med       Date:  1995-09       Impact factor: 53.440

5.  RASMOL: biomolecular graphics for all.

Authors:  R A Sayle; E J Milner-White
Journal:  Trends Biochem Sci       Date:  1995-09       Impact factor: 13.807

6.  Solution structure of the epithelial cadherin domain responsible for selective cell adhesion.

Authors:  M Overduin; T S Harvey; S Bagby; K I Tong; P Yau; M Takeichi; M Ikura
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

7.  Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex.

Authors:  Y Bourne; P Taylor; P Marchot
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

8.  Genetic engineering of snake toxins. The functional site of Erabutoxin a, as delineated by site-directed mutagenesis, includes variant residues.

Authors:  O Trémeau; C Lemaire; P Drevet; S Pinkasfeld; F Ducancel; J C Boulain; A Ménez
Journal:  J Biol Chem       Date:  1995-04-21       Impact factor: 5.157

9.  Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 A resolution.

Authors:  E Y Jones; K Harlos; M J Bottomley; R C Robinson; P C Driscoll; R M Edwards; J M Clements; T J Dudgeon; D I Stuart
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

10.  Primate terminal complement inhibitor homologues of human CD59.

Authors:  W L Fodor; S A Rollins; S Bianco-Caron; W V Burton; E R Guilmette; R P Rother; G B Zavoico; S P Squinto
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

View more
  39 in total

Review 1.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

2.  Molecular basis for a link between complement and the vascular complications of diabetes.

Authors:  J Acosta; J Hettinga; R Flückiger; N Krumrei; A Goldfine; L Angarita; J Halperin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 3.  Role of complement and complement regulatory proteins in the complications of diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Michael Chorev; Jose A Halperin
Journal:  Endocr Rev       Date:  2015-04-10       Impact factor: 19.871

4.  Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies.

Authors:  Linda Mark; David G Proctor; David J Blackbourn; Anna M Blom; O Brad Spiller
Journal:  Immunology       Date:  2007-08-30       Impact factor: 7.397

Review 5.  GPIHBP1, a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins.

Authors:  Anne P Beigneux; Brandon S J Davies; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-10-14       Impact factor: 5.922

6.  Generation and phenotyping of mCd59a and mCd59b double-knockout mice.

Authors:  Xuebin Qin; Weiguo Hu; Wenping Song; Luciano Grubissich; Xuemei Hu; Gongxiong Wu; Sean Ferris; Martin Dobarro; Jose A Halperin
Journal:  Am J Hematol       Date:  2009-02       Impact factor: 10.047

7.  Targeting of functional antibody-CD59 fusion proteins to a cell surface.

Authors:  H F Zhang; J Yu; E Bajwa; S L Morrison; S Tomlinson
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

8.  A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Sonia Cantel; Amol Kavishwar; Allison Goldfine; Neil Herring; Lynn Bry; Michael Chorev; Jose A Halperin
Journal:  Am J Hematol       Date:  2013-06-20       Impact factor: 10.047

9.  CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?

Authors:  Baalasubramanian Sivasankar; M Paula Longhi; Kathleen M E Gallagher; Gareth J Betts; B Paul Morgan; Andrew J Godkin; Awen M Gallimore
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

10.  Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59.

Authors:  Timothy R Hughes; Kirsty S Ross; Graeme J M Cowan; Baalasubramanian Sivasankar; Claire L Harris; Timothy J Mitchell; B Paul Morgan
Journal:  Mol Immunol       Date:  2009-02-06       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.